JCO Global Oncology (Nov 2020)

Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center

  • Hasmukh Jain,
  • Karthik Rengaraj,
  • Vibhor Sharma,
  • Avinash Bonda,
  • Raajit Chanana,
  • Jayashree Thorat,
  • Ashwini Ronghe,
  • Sanjay Biswas,
  • Lingaraj Nayak,
  • Prashant Tembhare,
  • Papagudi Subramnian,
  • Dhanalaxmi Shetty,
  • Nikhil Patkar,
  • Bhausaheb Bagal,
  • Manju Sengar

DOI
https://doi.org/10.1200/GO.20.00240
Journal volume & issue
no. 6
pp. 1684 – 1695

Abstract

Read online

PURPOSEInfections remain a major challenge in the treatment of acute myeloid leukemia (AML). Induction-related mortality reported in the literature is approximately < 5% in clinical trials. However, the real-world scenario is different, especially in developing countries, given the high incidence of multidrug-resistant (MDR) organisms, high incidence of fungal pneumonia at baseline, and significant delay before initiation of chemotherapy. We aimed to look at contemporary infections and infection-related mortality and analyze the patterns of infections.MATERIALS AND METHODSThis retrospective study was conducted at a large tertiary care oncology center in India. Patients with newly diagnosed AML who were older than age 15 years, considered fit for intensive therapy, and treated in the general wards of the adult hematolymphoid unit from March 1, 2014, until December 31, 2015, were included.RESULTSOne hundred twenty-one patients were treated during the study period. The most common presenting complaint was fever (85%). The focus of infection at presentation was found in 63% of patients, with respiratory infection being the most common (47%). MDR organisms were isolated in 55% of patients during induction from various foci. Klebsiella pneumoniae was the most common blood culture isolate (42.9%). Fungal pneumonia was diagnosed in 55% of patients during induction despite antifungal prophylaxis. Treatment-related mortality was 10.7% in all phases, with an induction mortality rate of 7.4%. Complete remission was attained in 69% of patients. Of all patients who received induction chemotherapy, 74% completed all three consolidation cycles. The 121 patients were followed up for a median period of 53 months. Four-year event-free survival was 35.8%, and 4-year overall survival was 41.5%.CONCLUSIONInfections and infection-related mortality are major challenges during AML induction. Gram-negative MDR and fungal infections are particularly common in our region.